IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF Art Unit: 1614

ULRICH POSANSKI Examiner: Roberts, Lezah

APPLICATION NO: 10/623,887

FILED: JULY 17, 2003

FOR: PHARMACEUTICAL COMPOSITIONS FOR SPARINGLY SOLUBLE

THERAPEUTIC AGENTS

MS: Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed July 16, 2004. Since it is being filed in accordance with 37 C.F.R. §1.97(c), a letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449. The documents cited on the form(s) PTO-1449 are in the English language, with the exception of items noted below.

Item AM (DE 27 53 526) is in the German language and is provided with an English abstract, which abstract provides a concise explanation of the relevance of this foreign language document.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Leslie Fischer

Attorney for Applicant Reg. No. 58,393

Patents Pharma

(862) 778-9308

2/16/09

Novartis Pharmaceuticals Corp.

One Health Plaza, Building 101

East Hanover, NJ 07936-1080